595 related articles for article (PubMed ID: 25851594)
1. Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL.
Fafá BP; Louzada-Junior P; Titton DC; Zandonade E; Ranza R; Laurindo I; Peçanha P; Ranzolin A; Hayata AL; Duarte A; Silveira IG; Costa I; Macieira JC; Guedes-Barbosa LS; Bertolo MB; Sauma MF; Silva MB; Freire M; Scheinberg MA; Fernandes V; Bianchi W; Miranda JR; Pinheiro GR; Carvalho HM; Brenol CV; Pereira IA; de Castro GR; de Morais JC; Oliveira SK; de Abreu MM; Toledo RA; Pinheiro MM; Vieira WP; Valim V;
Clin Rheumatol; 2015 May; 34(5):921-7. PubMed ID: 25851594
[TBL] [Abstract][Full Text] [Related]
2. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
[TBL] [Abstract][Full Text] [Related]
3. Reasons for Discontinuation and Adverse Effects of TNFα Inhibitors in a Cohort of Patients With Rheumatoid Arthritis and Ankylosing Spondylitis.
García-Lagunar MH; Gutiérrez-Cívicos MR; García-Simón MS; Conesa-Zamora P; Jimenez-Santos E; Cano-Vivar P; García-Márquez A; Muñoz-García I; Viney AC
Ann Pharmacother; 2017 May; 51(5):388-393. PubMed ID: 27920336
[TBL] [Abstract][Full Text] [Related]
4. Retention rates of adalimumab, etanercept and infliximab as first-line biotherapy agent for rheumatoid arthritis patients in daily practice - Auvergne experience.
Soubrier M; Pereira B; Frayssac T; Fan A; Couderc M; Malochet-Guinamand S; Mathieu S; Tatar Z; Tournadre A; Dubost JJ
Int J Rheum Dis; 2018 Nov; 21(11):1924-1932. PubMed ID: 28901727
[TBL] [Abstract][Full Text] [Related]
5. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
[TBL] [Abstract][Full Text] [Related]
6. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register.
Lie E; Lindström U; Zverkova-Sandström T; Olsen IC; Forsblad-d'Elia H; Askling J; Kapetanovic MC; Kristensen LE; Jacobsson LTH
Ann Rheum Dis; 2017 Sep; 76(9):1515-1521. PubMed ID: 28254789
[TBL] [Abstract][Full Text] [Related]
7. Retention rates of adalimumab, etanercept, and infliximab as first- or second-line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France).
Soubrier M; Pereira B; Fan A; Frayssac T; Couderc M; Malochet-Guinamand S; Mathieu S; Tatar Z; Tournadre A; Dubost JJ
Int J Rheum Dis; 2018 Nov; 21(11):1986-1992. PubMed ID: 30168265
[TBL] [Abstract][Full Text] [Related]
8. Switching from an anti-TNF monoclonal antibody to soluble TNF-receptor yields better results than vice versa: An observational retrospective study of 72 rheumatoid arthritis switchers.
Lequerré T; Farran É; Ménard JF; Kozyreff-Meurice M; Vandhuick T; Tharasse C; Pouplin S; Daragon A; Le Loët X; Varin R; Vittecoq O
Joint Bone Spine; 2015 Oct; 82(5):330-7. PubMed ID: 25864942
[TBL] [Abstract][Full Text] [Related]
9. Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database.
Scirè CA; Caporali R; Sarzi-Puttini P; Frediani B; Di Franco M; Tincani A; Sinigaglia L; Sfriso P; Tirri R; Bellis E; Delsante G; Porru G; Salaffi F; Giuggioli D; Rossini M; Todoerti M; Bazzichi L; Govoni M; Gerli R; Raschetti R; Minisola G; Montecucco C; Todesco S;
Clin Exp Rheumatol; 2013; 31(6):857-63. PubMed ID: 23981363
[TBL] [Abstract][Full Text] [Related]
10. Sustained Remission in Tumor Necrosis Factor Inhibitor-treated Patients with Rheumatoid Arthritis: A Population-based Cohort Study.
Einarsson JT; Geborek P; Saxne T; Kapetanovic MC
J Rheumatol; 2015 May; 42(5):741-8. PubMed ID: 25684762
[TBL] [Abstract][Full Text] [Related]
11. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
Favalli EG; Pregnolato F; Biggioggero M; Becciolini A; Penatti AE; Marchesoni A; Meroni PL
Arthritis Care Res (Hoboken); 2016 Apr; 68(4):432-9. PubMed ID: 26556048
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
[TBL] [Abstract][Full Text] [Related]
13. Comparison of continuation rates with three TNFα antagonists (adalimumab, infliximab, etanercept) in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: Retrospective 10-year study.
Batteux B; Devauchelle A; Boyard PL; Sejourné A; Fardellone P; Goëb V
Joint Bone Spine; 2016 Oct; 83(5):607-9. PubMed ID: 26919803
[No Abstract] [Full Text] [Related]
14. Incidence of tuberculosis among patients with rheumatoid arthritis using TNF blockers in Brazil: data from the Brazilian Registry of Biological Therapies in Rheumatic Diseases (Registro Brasileiro de Monitoração de Terapias Biológicas - BiobadaBrasil).
Yonekura CL; Oliveira RDR; Titton DC; Ranza R; Ranzolin A; Hayata AL; Duarte Â; Silveira IG; Carvalho HMDS; Moraes JCB; Abreu MM; Valim V; Bianchi W; Brenol CV; Pereira IA; Costa I; Macieira JC; Miranda JRS; Guedes-Barbosa LS; Bertolo MB; Sauma MFLDC; Silva MBG; Freire M; Scheinberg MA; Toledo RA; Oliveira SKF; Fernandes V; Pinheiro MM; Castro G; Vieira WP; Baaklini CE; Ruffino-Netto A; Pinheiro GDRC; Laurindo IMM; Louzada-Junior P
Rev Bras Reumatol Engl Ed; 2017; 57 Suppl 2():477-483. PubMed ID: 28739353
[TBL] [Abstract][Full Text] [Related]
15. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.
Hyrich KL; Lunt M; Watson KD; Symmons DP; Silman AJ;
Arthritis Rheum; 2007 Jan; 56(1):13-20. PubMed ID: 17195186
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs.
Perrotta FM; Addimanda O; Ramonda R; D'Angelo S; Lubrano E; Marchesoni A; Olivieri I; Punzi L; Salvarani C; Spadaro A
Reumatismo; 2014 Nov; 66(3):208-14. PubMed ID: 25376955
[TBL] [Abstract][Full Text] [Related]
17. Drug survival rates of tumor necrosis factor inhibitors in patients with rheumatoid arthritis and ankylosing spondylitis.
Kang JH; Park DJ; Lee JW; Lee KE; Wen L; Kim TJ; Park YW; Lee SS
J Korean Med Sci; 2014 Sep; 29(9):1205-11. PubMed ID: 25246737
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and Drug Survival of TNF Inhibitors in the Treatment of Ankylosing Spondylitis: A Prospective Cohort Study.
Heinonen AV; Aaltonen KJ; Joensuu JT; Lähteenmäki JP; Pertovaara MI; Romu MK; Hirvonen HE; Similä AK; Blom ML; Nordström DC
J Rheumatol; 2015 Dec; 42(12):2339-46. PubMed ID: 26472421
[TBL] [Abstract][Full Text] [Related]
19. An examination of the mechanisms involved in secondary clinical failure to adalimumab or etanercept in inflammatory arthropathies.
Bandrés Ciga S; Salvatierra J; López-Sidro M; García-Sánchez A; Durán R; Vives F; Raya-Álvarez E
J Clin Rheumatol; 2015 Apr; 21(3):115-9. PubMed ID: 25807089
[TBL] [Abstract][Full Text] [Related]
20. Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis.
Cannon GW; DuVall SL; Haroldsen CL; Caplan L; Curtis JR; Michaud K; Mikuls TR; Reimold A; Collier DH; Harrison DJ; Joseph GJ; Sauer BC
J Rheumatol; 2014 Oct; 41(10):1935-43. PubMed ID: 25128516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
